Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)—Protocol for a randomised clinical trial comparing a lower vs a higher oxygenation target in adults with acute hypoxaemic respiratory failure

Olav L. Schjørring1,2,3 | Anders Perner3,4 | Jørn Wetterslev3,5 | Theis Lange3,6,7 | Frederik Keus8 | Jon H. Laake9 | Marjatta Okkonen10 | Martin Siegemund11 | Matthew Morgan12,13 | Katrin M. Thormar14 | Bodil S. Rasmussen1,2,3 | and the HOT-ICU Investigators

1Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital, Aalborg, Denmark
2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
3Centre for Research in Intensive Care (CRIC), Copenhagen, Denmark
4Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
5Copenhagen Trial Unit, Department 7812, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
6Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
7Center for Statistical Science, Peking University, Peking, China
8Department of Critical Care, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
9Division of Emergencies and Critical Care, Oslo University Hospital, Rikshospitalet, Oslo, Norway
10Department of Perioperative, Intensive Care and Pain Medicine, Helsinki University Hospital, Helsinki, Finland
11Department of Anaesthesia and Intensive Care, University Hospital Basel, Basel, Switzerland
12Critical Care Research, University Hospital of Wales, Cardiff, UK
13Cardiff University School of Medicine, Wales, UK
14Department of Anaesthesia and Intensive Care, University Hospital Reykjavik, Landspitali, Reykjavik, Iceland

Background: Acutely ill adults with hypoxaemic respiratory failure are at risk of life-threatening hypoxia, and thus oxygen is often administered liberally. Excessive oxygen use may, however, increase the number of serious adverse events, including death. Establishing the optimal oxygenation level is important as existing evidence is of low quality. We hypothesise that targeting an arterial partial pressure of oxygen (PaO₂) of 8 kPa is superior to targeting a PaO₂ of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure.

Methods: The Handling Oxygenation Targets in the ICU (HOT-ICU) trial is an outcome assessment blinded, multicentre, randomised, parallel-group trial targeting PaO₂ in acutely ill adults with hypoxaemic respiratory failure within 12 hours after ICU admission. Patients are randomised 1:1 to one of the two PaO₂ targets throughout ICU stay until a maximum of 90 days. The primary outcome is 90-day mortality. Secondary outcomes are serious adverse events in the ICU, days alive without organ support and days alive out of hospital in the 90-day period; mortality, health-related
**1 | INTRODUCTION**

Oxygen is essential to sustain human life and thus patients with acute hypoxaemic respiratory failure admitted to the intensive care unit (ICU) are all treated with supplemental inspired medical oxygen to avoid life-threatening hypoxia. In the ICU setting, oxygen therapy is guided by descriptive studies,1,2 four small randomised clinical trials (RCTs)3-6 and small before-and-after trials,7,8 all indicating harmful effects of excessive oxygen supplementation. A recent meta-analysis of trials in acutely ill patients overall underlined the potential detrimental effect of hyperoxaemia. Nevertheless, the tendency in ICUs is towards a liberal use of oxygen therapy10-22 and noteworthy, despite self-reported restrictive preferences among ICU nurses and physicians.23-26 Importantly, hypoxaemia is associated with increased mortality10,12,18,27 as it may lead to a low tissue oxygen tension (PO2). The ‘critical’ tissue PO2 however, defined as the value below which oxidative cellular metabolism fails, is not measurable in daily clinical practice, but it is as low as 0.13 kPa in isolated mitochondria.28 Therefore, since only global oxygenation can be measured, liberal use of oxygen is likely to provide a too wide buffer of safety against life-threatening hypoxia. The potential harmful adverse effects of hyperoxaemia includes direct or indirect cellular damage mediated by reactive oxygen species,29-33 hyperoxaemic vasoconstriction34,35 with following paradoxical risk of tissue hypoxia, and formation of absorption atelectases.36-38 Targeting sub-normal oxygenation levels may, however, increase the risk of sudden desaturations due to the proximity to the steep slope of the oxygen dissociation curve.39 This emphasises the importance of continuous pulse oximetry during restrictive oxygenation practices, and vigilance of the nursing staff to avoid or minimise episodes of definitive hypoxaemia. When such precautions are taken however, an oxygenation target of 8 kPa may be superior to the conventional liberal approach of oxygen supplementation observed in current clinical practice.10-22 Restrictive oxygenation is recommended in patients with chronic obstructive pulmonary disease (COPD) outside the ICUs targeting an arterial oxygen saturation measured by pulse oximetry (SpO2) of 88% to 92%,40,41; in ICU patients with acute respiratory distress syndrome (ARDS) ‘low normoxaemia’ defined as an arterial partial pressure of oxygen (PaO2) from 7.3 to 10.7 kPa is often targeted,42,43 however, not recommended in current clinical guidelines due to lack of evidence.44,45

**Conclusion:** The HOT-ICU trial will test the hypothesis that a lower oxygenation target reduces 90-day mortality compared with a higher oxygenation target in adult ICU patients with acute hypoxaemic respiratory failure.

**Editorial Comment**

This is the protocol for the largest ongoing multinational randomised clinical trial on higher vs lower oxygenation targets in the ICU. It is set to be one of the most important ICU trials, guiding oxygenation targets for critically ill patients globally.

The optimal level of oxygenation in ICU patients remains unknown, especially when oxygenation levels are not definitively hyperoxaemic. Hence, trials in ICU patients comparing ‘strict normoxaemia’ defined as within the normal reference range of PaO2 from approximately 10.7 to 13.3 kPa46 to ‘low normoxaemia’ are urgently needed.

A target PaO2 of 8 kPa and a target PaO2 of 12 kPa would both not a priori be considered beneficial or harmful. Therefore, whichever target performs best with respect to all-cause mortality, serious adverse events (SAEs), use of life support in the ICU and health-related quality-of-life has to be investigated in a large, pragmatic, randomised trial with the lowest possible risk of bias.

We hypothesise that targeting a PaO2 of 8 kPa reduces 90-day mortality compared with targeting a PaO2 of 12 kPa in adult patients with hypoxaemic respiratory failure who are acutely admitted to the ICU.

**2 | METHODS**

**2.1 | Trial design**

The Handling Oxygenation Targets in the ICU (HOT-ICU) trial is an investigator-initiated, pragmatic, international, multicentre, randomised, outcome-assessor blinded, parallel-group trial of a lower oxygenation target vs a higher oxygenation target in adult patients with acute hypoxaemic respiratory failure acutely admitted to the ICU. Patients are randomised 1:1 within 12 hours after ICU admission and stratified by site, known COPD, and active haematological malignancy.

The protocol has been written according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement.47 The SPIRIT 2013 checklist is presented in Appendix
S1. A preliminary systematic review on the effect of lower vs higher oxygenation targets on mortality, including a trial sequential analysis was conducted as recommended. The preliminary analysis revealed no evidence to support neither a high nor a low oxygenation target.

2.2 | Registration

The trial was prospectively registered at European clinical trials database (EudraCT number 2017-000632-34) and at ClinicalTrials.gov (Identifier: NCT03174002), registered June 2, 2017.

2.3 | Setting

Intensive care units in university and non-university hospitals in Denmark, Finland, the Netherlands, Norway, Switzerland, the United Kingdom and Iceland that admit adult patients. A complete list of including sites can be found at ClinicalTrials.gov (Identifier: NCT03174002).

2.4 | Inclusion criteria

Patients aged 18 years or older, acutely admitted to the ICU, having an arterial line for PaO$_2$ monitoring, and receiving supplemental oxygen with a flow of at least 10 litres per minute in an open system irrespective of any flow of atmospheric air, or a fraction of inspired oxygen (FiO$_2$) of at least 0.50 in a closed system including invasive or non-invasive ventilation or continuous positive airway pressure (CPAP) systems, and who are expected to receive supplemental oxygen for at least 24 hours in the ICU, will be evaluated for participation.

2.5 | Exclusion criteria

Patients will be excluded from the trial if they meet any of the following criteria: (a) cannot be randomised within 12 hours of ICU admission, (b) receives chronic mechanical ventilation for any reason, (c) home supplemental oxygen use, (d) previously treated with bleomycin, (e) solid organ transplant planned or conducted during current hospital admission, (f) withdrawal from active therapy or brain death is deemed imminent, (g) pregnancy, that is, fertile woman with positive human chorionic gonadotropin (hCG) or plasma-hCG, (h) carbon monoxide poisoning, (i) cyanide poisoning, (j) methaemoglobinæmia, (k) paraquat poisoning, (l) any condition expected to involve the use of hyperbaric oxygen therapy, (m) sickle cell disease, (n) consent not obtainable according to national regulations and (o) previously randomised into the HOT-ICU trial.

2.6 | Screening and randomisation

All patients fulfilling the inclusion criteria within 12 hours from ICU admission will be screened by local investigators using a central web-based screening system. Patients are eligible if they fulfill all inclusion criteria and none of the exclusion criteria. Eligible patients will be randomised 1:1 via the screening system using a computer-generated allocation sequence list according to the stratification variables, and permuted blocks of varying sizes; all processes are concealed for patients, clinicians and trial investigators.

Inclusion and exclusion of patients will be reported as according to the Consolidated Standards of Reporting Trials (CONSORT) statement.

2.7 | Interventions

Enrolled patients will be randomly allocated to a PaO$_2$ oxygenation target equal to 8 kPa (60 mm Hg) or a PaO$_2$ oxygenation target equal to 12 kPa (90 mm Hg) throughout the length of stay in the ICU, including any readmissions up until 90 days from randomisation. The oxygenation target will be achieved by titration of the FiO$_2$ from 0.21 to 1.00 in both intervention groups. Deviation above the allocated oxygenation target will be allowed only if FiO$_2$ = 0.21 and deviation below the allocated oxygenation target will be allowed only if FiO$_2$ = 1.00. Given the pragmatic design of the trial, choice of oxygen supplementation devices and ventilator settings other than the FiO$_2$ are at the discretion of the treating clinicians. Ventilator settings will be registered daily enabling assessment of any intervention group differences other than the FiO$_2$ in the subgroup of mechanically ventilated patients. In both intervention groups, additional oxygen supplementation during ICU procedures, as well as during transportation, surgery and radiological examinations will be at the discretion of the treating clinicians; however, it will be requested to maintain the assigned oxygenation target whenever possible. Pre-oxygenation with FiO$_2$ = 1.0 prior to or during endotracheal procedures should be avoided if possible, alternatively, pre-oxygenation for a maximum duration of 1 minute prior to endotracheal suction and for a maximum duration of 3 minutes prior to intubation is allowed.

2.8 | Withdrawal and discontinuation of trial intervention

Patients will be withdrawn from the trial intervention at any time if informed consent is retracted or not given as according to national regulations. Data registration from a withdrawn patient will continue, unless consent for this is also withdrawn. If a patient experiences a suspected unexpected serious adverse reaction (SUSAR) related to oxygen supplementation, the patient will be withdrawn from the trial immediately; data registration will, however, continue. In all withdrawn patients, trial intervention will be stopped and further oxygen supplementation in the ICU will be at the discretion of the treating clinicians. Patients withdrawn from the trial, were data can be acquired as according to national regulations, will be followed up and included in the intention-to-treat analyses as well as in the per-protocol analyses if the criteria for these are met.
Patients transferred to an ICU participating in the HOT-ICU trial will keep the allocated oxygenation target during ICU admission up until 90 days after randomisation. Patients transferred to an ICU not participating in HOT-ICU will be considered discharged from the ICU. All patients will be followed up for the primary outcome, and for as many of the secondary outcomes as possible through national registers, phone calls, and/or patient charts.

A patient can be discontinued from the intervention by the clinicians at any time if the patient experiences intolerable adverse events believed to be related to the trial intervention. In these cases, the oxygenation target should be reinstalled if the trial intervention at a later point is considered safe by the treating clinicians. In either case, the patient remains in the trial and will be included in the intention-to-treat population, and per-protocol populations if the criteria are met.

Flawed randomisations, that is, patients found not to have fulfilled the inclusion criteria at randomisation, or who fulfilled one or more of the exclusion criteria at randomisation, will remain in the trial.

2.9 | Outcome measures

The primary outcome measure is all-cause mortality 90 days after randomisation. Secondary outcome measures include: (a) number of patients with one or more SAE in the ICU after randomisation defined as new episode of shock, new episodes of myocardial or intestinal ischaemia or ischaemic stroke; (b) days alive without the use of respiratory support, renal replacement therapy or circulatory support in the 90-day period; (c) days alive and out of hospital in the 90-day period; (d) mortality 1 year after randomisation; (e) health-related quality-of-life assessed by EuroQol 5 dimensions 5 level questionnaire and EQ visual analogue scale (EQ-5D-5L); (f) cognitive function 1 year after randomisation assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at selected sites; (g) a health economic analysis, the analytic details will be based on the result of the trial and specified later on (cost-effectiveness vs cost-minimisation analyses); and (h) pulmonary function 1 year after randomisation at selected sites as assessed using whole body plethysmography and diffusion capacity. This latter outcome has been planned post hoc.

The specific elements of the above composite outcomes will be reported in a supplement to the primary publication.

An overview of the enrolment, interventions and assessments procedures as according to the SPIRIT 2013 statement is presented in Table 1.

2.10 | Blinding

The trial intervention is not blinded for investigators, clinicians or patients. The primary outcome of 90-day mortality will be drawn from electronic patient systems relying on central national registers and will thus be assessed blinded. Similar procedure is applied for the secondary outcome of 1-year mortality. EQ-5D-5L and RBANS interviews, as well as pulmonary function tests will be conducted by research staff members who are not employed in the ICUs, without access to the eCRF or patient files and thus blinded to the trial interventions. Since local investigators will provide all other outcomes from the patients’ medical files, blinding of outcome assessment is not feasible for these remaining outcomes. The trial statistician will be blinded for the allocation during all analyses. The members of the data monitoring and safety committee (DMSC) will remain blinded unless 1) they request otherwise or 2) the interim analysis has provided strong indications of one of the interventions being harmful. The writing committee will remain blinded for the allocation while drafting the abstract for the primary publication.

2.11 | Subgroups

We will compare the primary outcome measure in five predefined subgroups (a) patients with shock at randomisation (yes/no), (b) patients receiving invasive mechanical ventilation at randomisation (yes/no), (c) type of ICU admission (medical/elective surgical/emergency surgical), (d) patients with known COPD at randomisation (yes/no) and (e) patients with acute traumatic brain injury at randomisation (yes/no). Furthermore, the primary outcome measure will be compared in four subgroups that were not pre-specified: (a) patients with active haematological malignancy (yes/no), (b) patients resuscitated from cardiac arrest prior to randomisation (yes/no), (c) patients with ARDS at randomisation (yes/no) and (d) patients receiving oxygen supplementation through a closed system at randomisation according to baseline PaO₂/FiO₂ ratio (c) PaO₂/FiO₂ ratio < 26.7 kPa; ≥26.7 to < 40.0 kPa; ≥40.0 kPa).

2.12 | Data registration and monitoring

All data will be entered into a central web-based, password protected, encrypted electronic case report form (eCRF) system supplied and supported by the Copenhagen Trial Unit using the clinical data management system OpenClinica® software (OpenClinica, LLC, Waltham, MA 02451, USA). Paper versions of the eCRF are used only during system malfunction. Details and definitions of the data collected are presented in Appendix S2.

Full external monitoring of registered data is applied at all trial sites following a monitoring plan developed in collaboration with the good clinical practice (GCP) unit at Aalborg and Aarhus University Hospitals according to GCP standards. Central monitoring is done by Sponsor using the eCRF data only.

2.13 | Adverse and serious adverse events

Selected SAEs as defined under secondary outcome measures will be registered daily in the eCRF. When an ischaemic SAE is registered (new myocardial ischaemia, new intestinal ischaemia or new ischaemic stroke) clinicians will be asked for possible relation to the
**TABLE 1** Overview of the schedule of enrolment, interventions and assessments as according to the SPIRIT 2013 statement

<table>
<thead>
<tr>
<th>TIMEPOINT</th>
<th>STUDY PERIOD</th>
<th>Enrolment</th>
<th>Allocation</th>
<th>Post-allocation (Days from randomisation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU admission (+ 0-12 hours)</td>
<td>ICU discharge /day 90</td>
<td>Follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TIMEPOINT</strong></td>
<td><strong>Enrolment</strong></td>
<td><strong>Allocation</strong></td>
<td><strong>Post-allocation</strong></td>
<td></td>
</tr>
<tr>
<td>ICU admission (+ 0-12 hours)</td>
<td>ICU discharge /day 90</td>
<td>Follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrolment</td>
<td>Allocation</td>
<td>Time of randomisation (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TIMEPOINT</strong></td>
<td><strong>Enrolment</strong></td>
<td><strong>Allocation</strong></td>
<td><strong>Post-allocation</strong></td>
<td></td>
</tr>
<tr>
<td>ICU admission (+ 0-12 hours)</td>
<td>ICU discharge /day 90</td>
<td>Follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrolment</td>
<td>Allocation</td>
<td>Time of randomisation (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TIMEPOINT</strong></td>
<td><strong>Enrolment</strong></td>
<td><strong>Allocation</strong></td>
<td><strong>Post-allocation</strong></td>
<td></td>
</tr>
<tr>
<td>ICU admission (+ 0-12 hours)</td>
<td>ICU discharge /day 90</td>
<td>Follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrolment</td>
<td>Allocation</td>
<td>Time of randomisation (0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ENROLMENT:**
- Eligibility screen: X
- Informed consent: X
- Allocation: X

**INTERVENTIONS:**
- Oxygenation target 8 kPa
- Oxygenation target 12 kPa

**ASSESSMENTS:**
- Baseline variables (general patient information, respiratory support, respiratory status, acute illness parameters, SOFA score and chronic comorbidities): X
- Mortality: X
- Serious adverse events in the ICU: X
- Days alive without organ support: X
- Days alive and out of hospital: X
- EuroQol (EQ-5D-5L): X
- Neuropsychological function (RBANS): X
- Pulmonary function: X

ICU: Intensive Care Unit; EQ-5D-5L: EuroQol 5 dimensions 5 level questionnaire and EQ visual analogue scale; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; SOFA: Sequential Organ Failure Assessment.

*At selected sites.
allocated oxygenation target. If a relation is suspected an automatic warning will be sent to the coordinating centre, hereby enabling the Sponsor to continuously evaluate trial safety and to decide whether it represents a serious adverse reaction or SUSAR and act accordingly. Any other SAEs according to the International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use GCP (ICH-GCP) definition\textsuperscript{54} will not be systematically recorded, but will be evaluated continuously by primary site investigators and co-investigators in their daily clinical practice.

The three adverse reactions to normobaric medical oxygen are atelectasis, pleuritis and ARDS\textsuperscript{55}; all common in critically ill patients admitted to the ICU with acute hypoxaemic respiratory failure. They are therefore indistinguishable from the adverse events caused by the underlying pulmonary pathophysiology. However, differences in the severity of atelectasis and of ARDS will be captured by daily registrations of FiO\textsubscript{2} and PaO\textsubscript{2} enabling the calculation of a PaO\textsubscript{2}/FiO\textsubscript{2} ratio.

If a patient experiences a SUSAR, this will be reported to the relevant authorities as required by the national and European regulations.

All trial sites have insurances for participating patients either through the national health insurances or through specifically supplied local trial insurances as required according to the specific trial sites and national regulations.

2.14 | Approvals

The HOT-ICU trial is approved by the Danish Health and Medicine Agency (AAUH-ICU-01, approved 31 May 2017), the Committee on Health Research Ethics in the North Denmark Region (N-20170015, approved 22 May 2017), the Danish Data Protection Agency (2008-58-0028, approved 27 March 2017) and by all required authorities in participating countries. All patients will be enrolled after consent to participate has been obtained as according to national regulations.

2.15 | Statistics

The primary analysis will be conducted in the intention-to-treat population\textsuperscript{54} being all randomised patients except those who were follow-up cannot be conducted due to withdrawal of consent as according to national regulations.\textsuperscript{54,57,58} The primary outcome of 90-day mortality in the intervention groups will be compared using a generalised linear model with a log-link and binomial error distribution with adjustment for stratification variables (site, known COPD and active haematological malignancy).\textsuperscript{59} Significance of the intervention will be assessed based on P-values from this regression analysis and risk ratios with 95% confidence intervals are readily available from it. The primary analysis will be supplemented with Kaplan-Meier plots (not accounting for stratification variables) and Cox proportional hazard models with adjustment for stratification variables.

A secondary analysis will be performed adjusting for the stratification variables and for major prognostic baseline differences: age, active metastatic cancer, type of admission (medical, elective surgical or emergency surgical) and baseline Sequential Organ Failure Assessment (SOFA) score.\textsuperscript{60}

One pre-planned sensitivity analysis will be conducted in the per-protocol population defined as all patients except those with one or more major protocol violations (MPVs); that is, both the highest and the lowest registered PaO\textsubscript{2} in one 12-hour interval from 06:00 to 18:00 or from 18:00 to 06:00 are at least 1.0 kPa above the PaO\textsubscript{2} target if both FiO\textsubscript{2}s are above 0.21, OR at least 1.0 kPa below the PaO\textsubscript{2} target if both FiO\textsubscript{2}s are below 1.00.

Three post-trial-initiation planned sensitivity analyses will be conducted. The first analysis will be the new primary per-protocol population, which excludes patients with an MPV as defined by the pre-planned per-protocol population in two or more consecutive 12-hour intervals, corresponding to the patient being at least 24 hours off target; only consecutive MPVs that deviate to the same side (either above OR below the allocated oxygenation target) will exclude the patient. The second sensitivity analysis will establish the impact of higher vs lower oxygenation overall. It excludes patients allocated to 12 kPa with MPVs deviating below the oxygenation target in two or more consecutive 12-hour intervals AND it excludes patients allocated to 8 kPa with MPVs deviating above the oxygenation target in two or more consecutive 12-hour intervals. In this sensitivity analysis the patients with MPVs, which draws the oxygenation groups towards each other, will be removed. The third sensitivity analysis will evaluate the impact of too-high or too-low oxygenation. It excludes patients allocated to 12 kPa with MPVs deviating above the oxygenation target in two or more consecutive 12-hour intervals AND it excludes patients allocated to 8 kPa with MPVs deviating below the oxygenation target in two or more consecutive 12-hour intervals. In this sensitivity analysis the patients with MPVs, which draws the oxygenation groups away from each other, will be removed.

A two-sided P value of less than 0.05 will be considered statistically significant. P-values for the secondary outcomes will be adjusted for multiple testing. We will present the intervention effect expressed as relative risk with 95% CIs in the overall population as well as in the planned subpopulations.

A predefined detailed statistical analyses plan including models for all secondary outcomes will be provided in a separate publication submitted prior to inclusion of last patient, or in the case that the trial is prematurely terminated, submitted prior to closure of the trial database.

2.16 | Sample size calculations

To detect or reject a true 20% relative risk reduction, achieving a maximal type 1 error of 5% and type 2 error (power) of 90%, we will randomise 2928 patients. The sample size estimation was based on a control group 90-day mortality (target PaO\textsubscript{2} of 12 kPa) of 25%\textsuperscript{27,61} and allocation 1:1 to the two groups. We will be able to detect or refute an absolute risk reduction of 5% point or more, corresponding
to a number needed to treat of 20 or less. To maintain power in the statistical analysis, we will adjust the primary analyses for the stratification variables.

2.17 | Data monitoring and safety committee (DMSC)

An independent DMSC will oversee the trial during the trial period following the predefined Charter for the DMSC (Appendix S3).

A planned interim analysis will be conducted when the first 1464 patients (50% of the sample size) have completed 90-day follow-up. The DMSC may request unplanned interim analyses at any time.

The DMSC may recommend pausing or stopping the trial if group-difference in the primary outcome measure or in SAEs are found in any interim analysis with statistical boundaries based on O’Brien-Fleming alpha-spending function. If an analysis of the interim data from the 1464 patients fulfils the Lan-DeMets stopping criterion, the inclusion of further patients will be paused and an analysis including all randomised patients will be performed. If this second analysis also fulfils the Lan-DeMets’ stopping criterion according to the group sequential monitoring boundaries, the Management Committee may stop the trial. Furthermore, the DMSC can recommend pausing or stopping the trial if continued conduct of the trial clearly compromises patient safety. However, stopping the trial due to expected futility of showing a 20% relative risk ratio reduction will not be an option as intervention effect <20% relative risk ratio reduction of all-cause mortality may be clinically relevant.

2.18 | Availability of data and material

The clean electronic trial database file will be delivered to the EudraCT Database and to the Danish Data Archive. All trial documents, including protocol amendments will be available on the public HOT-ICU trial website (http://www.cric.nu/hot-icu) and communicated to relevant parties through monthly newsletters. The trial results will be sought published in a relevant peer reviewed scientific journal and linked to the trial website.

3 | DISCUSSION

Oxygen is a medicine that has been used for decades with a continuing tendency towards liberal use. This is highlighted in recently published observational studies in critically ill patients admitted to ICUs in Europe, New Zealand and Australia and in the US, all showing U-shaped associations between arterial oxygenation and mortality. Noteworthy, the PaO2 associated with the lowest mortality was highly variable in these studies—from 10 kPa to as high as 40 kPa. Taking the observational study design into consideration however, causality cannot be assumed, and the associations found may merely represent differences in disease severity or be reflections of the preferred oxygenation levels in the included ICUs. Therefore, the optimal target interval resulting in the lowest mortality risk remains uncertain. Several RCTs on liberal vs conservative oxygen therapy in heterogeneous groups of acutely ill patients and in various clinical settings have been conducted. These trials were recently grouped in a systematic review and meta-analysis, which concluded that there is high-quality evidence showing that liberal oxygen therapy increases mortality without improving other patient-important outcomes. However, the oxygenation targets of the included trials were highly variable, as were the intended durations of the interventions, ranging from 1 to 144 hours. Importantly, trials in patients with and without respiratory failure were included in the analysis. Only three of the included trials were conducted in ICU patients, of which the trial with the highest weight (32%), was stopped prematurely after an unplanned interim analysis. Based on supplementary analysis, the authors of the systematic review concluded that treatment with oxygen could become unfavourable in acutely ill patients if resulting in an SpO2 above 94%-96%. However, this specific upper target of SpO2 is not supported by the trials with the highest weight in the mortality analysis, as these studies effectively all investigated normoxaemia vs hyperoxaemia with SpO2 above 94%-96% in the conservative oxygenation groups. Nevertheless, this upper SpO2 target has recently been implemented in a clinical guideline on oxygen therapy. Despite this guideline being published, several questions remain unanswered. Most importantly, how will oxygenation targets of strict normoxaemia vs low normoxaemia affect short- and long-term patient-important outcomes in patients admitted to the ICU, and in those with hypoxaemic respiratory failure? The HOT-ICU trial aims to answer these important questions.

The trial will include patients with hypoxaemic respiratory failure only, and the level of oxygen supplementation defines the patients as being hypoxaemic in the pragmatic trial design. The reason for not using PaO2 as part of the inclusion criterion is based on the assumption that physicians will not give supplementary oxygen over the designated threshold in patients without hypoxaemic respiratory failure. As the threshold of oxygen supplementation is high, we expect that all patients included will have hypoxaemic respiratory failure with a PaO2/FiO2 ratio below 40 kPa. The oxygenation targets in the HOT-ICU trial are defined by PaO2 levels. The choice of PaO2 over arterial oxygen saturation (SaO2) or SpO2 as target parameter is based on the fact that the level of hyperoxaemia is uncontrollable if using only the SaO2 or SpO2 due to the sigmoid shape of the oxygen dissociation curve. Therefore, if SaO2 or SpO2 above 95% defines the oxygenation target, uncontrollable levels of hyperoxaemia will occur as underlined in a recent observational study. Additionally, ICU doctors in Northern Europe prefer using PaO2 over SaO2 as the target parameter for oxygenation. The choice of protocolling a fixed normoxaemic oxygenation target in the control group rather than standard care at clinicians’ discretion is based on the large variation in oxygenation levels observed in ICU cohorts worldwide with median and
mean PaO\textsubscript{2} levels ranging from 9.8 to 23.0 kPa.\textsuperscript{10-12,14-16,18} As the HOT-ICU trial is international, a highly variable approach to oxygen supplementation can be assumed, thus a non-protocolled standard care in the control group would induce a risk of masking any deductions about the actual oxygenation strategy used. Furthermore, a pilot trial\textsuperscript{4} which confirmed equipoise of the intervention groups in the HOT-ICU trial, used a protocollled oxygenation target in the liberal oxygenation control group, a target that corresponds to the higher oxygenation target of 12 kPa in the HOT-ICU trial.

The choice of mortality as primary outcome is based on the high mortality rates in ICU patients\textsuperscript{70} and in mechanically ventilated patients in particular,\textsuperscript{71} and on the probability of detecting a difference in mortality by interventions in the ICU, especially for life-support interventions. Only mortality as the primary outcome will weigh the totality of the potential positive and negative effects of a higher vs a lower oxygenation strategy. Finally, the recent systematic review,\textsuperscript{9} which suggested reduced all-cause mortality with conservative oxygen therapies in acutely ill patients overall, further justifies the choice of mortality as the primary outcome.

4 | PERSPECTIVE

The design of the HOT-ICU trial aims to minimise the risk of systematic errors and the trial will provide valuable information on benefits and/or harmful effects of an oxygenation target of either 8 kPa or an oxygenation target of 12 kPa in patients acutely admitted to the ICU with need of oxygen supplementation due to hypoxaemic respiratory failure, including both short-term and long-term outcomes. Being the largest trial on the subject, the trial will add considerably to the cumulated evidence and to the overall knowledge of optimal oxygenation targets in the ICU, with the potential to reduce both mortality and morbidity as well as costs in the ICU. The HOT-ICU trial will assist in guiding future clinical practice, ensuring a more evidence-based use of medical oxygen in the ICU.

5 | TRIAL STATUS

The trial is currently recruiting at 28 active sites. The first patient was randomised on the 20th of June 2017. At present (22 January 2019), 1291 patients have been included. The current protocol version is version 2.0 of 12 December 2018. The last patient is expected to be included ultimo 2019.

ACKNOWLEDGEMENTS

We thank the participating patients and relatives, site investigators and the clinical staff at all trial sites, the DMSC members (professor Jean-François Timsit, Bichat Teaching Hospital, Paris Diderot University, Paris, France; professor Daniel De Backer, the Free University Hospital, Brussels, Belgium; and assistant professor Andreas Kryger Jensen, Section of Biostatistics, Department of Public Health, University of Copenhagen, Denmark), our funding sources and Centre for Research in Intensive Care (CRIC).

CONFLICT OF INTEREST

The Department of Intensive Care, Rigshospitalet has received funds for research from Fresenius Kabi, CSL Behring and Ferring Pharmaceuticals.

AUTHORS’ CONTRIBUTIONS

OLS and BSR drafted the protocol and the manuscript for this paper in close collaboration with AP, JW and TL. FK, JHL, MO, MS, MM and KMT all made substantial contributions to the process of developing the protocol and contributed with scientific input for the protocol and for this manuscript. All authors have read and approved the final manuscript. All authors are members of the HOT-ICU Steering Committee with BSR as sponsor and principal investigator of the HOT-ICU trial, OLS as coordinating investigator and FK, JHL, MO, MS, MM, KMT and OLS as national principal investigators. The HOT-ICU Management Committee consists of BSR, OLS, AP, JW and TL. The Management Committee will draft the final article.

ORCID

Olav L. Schjørring https://orcid.org/0000-0002-7749-6003
Anders Perner https://orcid.org/0000-0002-4668-0123
Jørn Wetterslev https://orcid.org/0000-0001-7778-1771
Theis Lange https://orcid.org/0000-0001-6807-8347
Frederik Keus https://orcid.org/0000-0003-1516-1475
Jon H. Laake https://orcid.org/0000-0001-6157-5359
Matthew Morgan https://orcid.org/0000-0002-2357-7190
Bodil S. Rasmussen https://orcid.org/0000-0003-2190-145X

REFERENCES


44. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clinical practice guideline on mechanical ventilation in adults with...


**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Schjørring OL, Perner A, Witterslev J, et al. Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)—Protocol for a randomised clinical trial comparing a lower vs a higher oxygenation target in adults with acute hypoxaemic respiratory failure. *Acta Anaesthesiol Scand.* 2019;63:956–965. [https://doi.org/10.1111/aas.13356](https://doi.org/10.1111/aas.13356)